Briefs & Briefing Documents

In addition to our tools and blog, ML&P occasionally delves into complex topics, posting brief explanations to make their legal implications more clear and understandable. We also undertake longer research projects, to more thoroughly explore issues and make policy recommendations. These are posted below.

Briefing Documents

How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine

How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine

The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not as clear, though, as it may first seem. Medicines Law & Policy has written a technical briefing note that contextualises the respective roles of Oxford University, the Jenner Institute, AstraZeneca and these other actors, and provides comments as well as raises some important questions about what might yet be done better and what lessons can be learned for the future. Click here to read it.

An ML&P series of briefing documents that aims to contribute to the discussion on high medicines prices in Europe, in particular those that result from market exclusivity.

EU Review of Pharmaceutical Incentives:
Suggestions for Change

In June 2019, Medicines Law & Policy published a series of briefing documents that aim to contribute to the discussion on high medicines prices, in particular those that result from market exclusivity. The publication makes recommendations for policy and legislative change in the areas of Supplementary Protection Certificate, Data Exclusivity, and Orphan Medicinal Product regulations. The documents can be downloaded in their entirety, or by section, using the links below. A presentation on the documents made at a 3 June event co-hosted by the European Public Health Alliance is available here.

Briefs

Ensuring that intellectual property rights aren’t a barrier to scaling-up: the remarkable example of...

This week various international bodies are tackling different challenges in meeting the urgent problem of scaling-up manufacture of and access to vaccines for Covid-19. On 13 April, the World Health Organization in cooperation with...

The European Commission says Covid-19 vaccines should be global public goods, but do their...

By Ellen 't Hoen & Pascale Boulet The European Commission has entered into advance purchase agreements (APAs) for Covid-19 vaccines with six pharmaceutical companies and is concluding negotiations with two companies. See here. The APAs have...

What is the ‘know-how gap’ problem and how might it impact scaling up production...

This entire article is also available as a PDF by clicking here. 1. Introduction. How relevant are concerns about intellectual property rights causing problems for scaling up production of Covid-19 related diagnostics, therapies and vaccines?...

How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine

The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not as clear, though, as it may first seem. The media...

Never say never – Why the High Income Countries that opted-out from the Art....

To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce or import (competing) generic versions of the patented medicine. Even...